Mechelen, Belgium; 24 May 2011- Galapagos NV (Euronext: GLPG) announced that four abstracts have been selected for presentation at the Annual European Congress of Rheumatology (EULAR) taking place 25-28 May 2011 at the ExCel Congress Centre in London. Presentations will include pre-clinical and early clinical findings on two programs: GLPG0634, a selective JAK1 inhibitor being developed for rheumatoid arthritis, and GLPG0259, a small molecule inhibitor of the kinase MAPKAPK5.
GLPG0634/JAK1 inhibitor:
- Preclinical and early clinical evaluation of GLPG0634, a selective JAK1 inhibitor for the treatment of rheumatoid arthritis (28-May, 10.15 – 12.00; Poster Session III, Abstract #SAT251)
GLPG0259/MAPKAPK5 inhibitor:
- Identification of GLPG0259, an orally bioavailable inhibitor of MAPKAPK5, as a clinical candidate for the treatment of rheumatoid arthritis (Interrupting signalling pathways – is specificity desirable? 27-May, 15.30-17.00; Capital Suite 02, Abstract #OP0292)
- GLPG0259, an inhibitor of novel target MAPKAPK5, dose-dependently reduces pro-inflammatory cytokines and MMPs and blocks disease progression in vivo (26-May, 11.45 – 11.30; Poster Session I, Abstract #THU0294)
- Safety and pharmacokinetic profile in healthy volunteers of GLPG0259, a small molecule MAPKAPK5 inhibitor (28-May, 10.15 – 12.00, Poster Session III, Abstract #SAT0249)
The full abstracts can be accessed through the EULAR conference website or www.eular.org. After the presentation and posters are presented they will be available in PDF format on Galapagos’ website: www.glpg.com.
For more information:
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com